Clinical Trial Update: REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy

View source ↗

Summary

This clinical trial update reports on refractoriness to ibrutinib, a Bruton Tyrosine Kinase inhibitor, and to systemic targeted therapies in chronic lymphocytic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Leukemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: CLL, Relapsed, CLL, Refractory | Status: COMPLETED